Rainbow Genomics Launches Polygenic and Trait Analysis for Obesity Management Using Whole Genome Sequencing

Genetic analysis of metabolic disorders coupled with assessment of nutrigenomics and adaptation traits to exercise allows for lifestyle changes to reduce obesity

SAN FRANCISCO, CA, UNITED STATES, Sept. 19, 2022 /EINPresswire.com/ — US and Hong Kong-based Rainbow Genomics is launching a comprehensive obesity genetic analysis program, including whole genome sequencing, to identify genomic variations associated with obesity Identifying metabolic disorders and responses to foods and nutrition, eating behavior and exercise adjustment.

Obesity is considered a chronic condition by many doctors, with body mass index (BMI) being one of the parameters that indicate high body fat and overweight. BMI is highly heritable, and over 40-70% of the variability in BMI can be explained by genetic factors. Obese people are prone to an increased risk of developing diabetes, heart disease, stroke and other metabolic diseases.

Part of the risk of obesity is transmitted by genetic variants, including mutations in a single gene and polygenic changes associated with multiple genes. Additional obesity risks are associated with genetic traits with strong behavioral traits, including appetite, eating behaviors, and exercise adaptation.

The Rainbow Comprehensive Obesity Genetic Analysis Program is part of the many reports provided by the Rainbow Adult 8000™ Whole Genome Sequencing Test. The test looks for monogenic mutations and polygenic risks associated with metabolic disorders. In addition, several Asian-specific genetic traits will also be determined, including genetic alterations associated with BMI, appetite, eating behaviors, dietary preferences, food intake abnormalities, and adaptations to different forms of exercise.

Also Read :  Bill Gates tells San Diego audience that genomics is key technology for dodging the next global pandemic

A comprehensive analysis of these results supports patients at risk for obesity in adopting modified diets and lifestyles that may reduce their risks. The multifaceted findings are explained to patients by a genetic counselor in plain English and Chinese. Patients with pathogenic mutations associated with obesity, metabolic, or cardiovascular disease are also referred to specialist physicians for follow-up care.

For more information about the Rainbow Comprehensive Obesity Genetic Analysis Program and the Rainbow Adult 8000™ Whole Genome Sequencing Test, please visit our website or email us at [email protected]

About the Rainbow Whole Genome Sequencing Test

The test provides five clinical reports:

1. Personal health assessment

• Cancer
• Cardiovascular diseases
• Abnormality of the endocrine system, including diabetes and fatty liver
• Sleep disorders
• Hearing and eye diseases
• Skeletal and bone diseases
• Immune system disorders
• Skin abnormality
• Autoinflammatory diseases
• Behavioral abnormality
• Neurological disorders including dementia and Alzheimer’s disease

2. Assessment of reproductive health

• Male infertility
• Female infertility

3. Whole Genome Carrier Status

• Carrier Screening Analysis of Disorders Recommended by the American College of Obstetricians and Gynecologists and the American College of Medical Genetics

Also Read :  Altered fat cells may fuel breast cancer tumor growth

• Whole genome carrier analysis – mutations in 2500 genes associated with recessive diseases that can be passed on to the patient’s children

4. Risk assessment for common diseases

• Common complex diseases such as diabetes, heart attack and stroke are mainly caused by changes in several gene variants (polygenic risks). However, these variants are highly ethnic specific. Polygenic risk assessment for ethnically specific groups such as Asians is difficult because very few publications are available with Asian patients and healthy controls with statistical significance.

• Rainbow Genomics’ expert-curated polygenic variants are highly race-specific and are supported by large-scale genome-wide association and replication studies involving tens of thousands of patients and controls across Asia, the US and European countries.

5. Pharmacogenomic evaluation of 185 drugs to improve clinical outcome

• In chronic diseases, achieving risk reduction goals by improving medication adherence is crucial. Pharmacogenomic evaluation enables high therapeutic efficacy by minimizing drug side effects, leading to better treatment outcomes.

6. Rainbow Comprehensive Obesity Genetic Analysis Program and Report

About Rainbow Genomics

Rainbow Genomics (www.rainbowgenomics.com) is committed to providing clinically validated genomic and proteomic tests for Asian, Caucasian, multiracial and local minorities. The company provides physicians with high diagnostic success and enables timely treatment of patients who can benefit from immediate medical interventions.

Also Read :  Take every bit of technology out of your child’s bedroom, says head of Girls’ School Association

Leveraging a multi-technology platform approach including proteomics, whole genome, whole exome, RNA, long read, methylation, single cell and Sanger sequencing, high resolution microarray testing and high density DNA array genotyping, and by several international Collaborating, Rainbow Genomics delivers diagnostic yield that meets or exceeds the highest standards reported by leading US and European medical institutions.

All Rainbow Genomics tests are performed in CLIA-certified and CAP-accredited clinical laboratories with high complexity. Patient privacy is protected by Rainbow’s HIPAA-compliant clinical testing process.

rainbow genomics
+852 3481 0977
[email protected]

Source link